Longeveron Inc. (LGVN)

Market Cap	46.14M
Revenue (ttm)	882,000
Net Income (ttm)	-19.98M
Shares Out	21.17M
EPS (ttm)	-0.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	37,589
Open	2.25
Previous Close	2.29
Day's Range	2.12 - 2.26
52-Week Range	2.12 - 4.81
Beta	0.43
Analysts	Strong Buy
Price Target	12.50 (+473.39%)
Earnings Date	Nov 13, 2023

About LGVN

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, an allogeneic medicinal signaling cell therapy product isolated from the bone marrow of young, healthy adult donors. It is conducting Phase 1, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. T...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 12, 2021
• Employees: 19
• Stock Exchange: NASDAQ
• Ticker Symbol: LGVN

Financial Performance

In 2022, Longeveron's revenue was $1.22 million, a decrease of -6.43% compared to the previous year's $1.31 million. Losses were -$18.84 million, 10.5% more than in 2021.

Analyst Forecast

According to 2 analysts, the average rating for LGVN stock is "Strong Buy." The 12-month stock price forecast is $12.5, which is an increase of 473.39% from the latest price.

Price Target

$12.5

(473.39% upside)

Analyst Consensus: Strong Buy